Abstract: This invention provides a novel pesticide composition having a bicarbonate-containing inorganic salt ingredient which exhibits fungicidal activity, and which enhances the efficacy of a C.sub.8 -C.sub.22 fatty acid insecticidal ingredient for the treatment of agricultural and horticultural plants. An invention pesticide composition also can contain a water-soluble organic compound which functions as a compatibility enhancing agent for the active ingredients, and improves the spreadability and adhesiveness of the composition ingredients when applied to foliage as an aqueous pesticide formulation.

Abstract: The invention relates to a process for the preparation of a tablet or dragee composition containing a moisture-, heat- and light-sensitive compounds having monoclinic crystalline structure as active ingredients, which comprises homogenizing the active ingredient with 0.2 to 1.5 parts by weight of an anhydrous alkaline earth metal salt and 0.5 to 2.5 parts by weight of microcrystalline cellulose calculated for the active ingredient and optionally with one or more pharmaceutically acceptable carrier(s) and/or additive(s) and compressing the homogeneous mixture obtained to tablets in a manner known per se and, if desired, coating the tablet thus obtained in a manner known per se.

Abstract: The lozenge or chewable tablet contains, as the base, at least 30, preferably 50 to 70, percent by weight of an alkali metal and/or alkaline earth metal salt of at least one edible, organic acid, at least 10, preferably 20 to 40, percent by weight of a mixture of at least one unreacted, edible organic acid with at least one unreacted alkali metal or alkaline earth metal carbonate and/or bicarbonate and, if required, a pharmaceutical active substance and/or other conventional tablet assistants, such as flavors and sweeteners, disintegrants, hydrocolloids, etc.

Abstract: An ophthalmologic composition therapeutic in the treatment of dry eye syndrome is disclosed. The composition is comprised of a minimally soluble salt of calcium that has been finely divided into particles having a mean diameter of 10 to 60 microns. The calcium salt particles are suspended within a pharmacologically acceptable carrier such as petrolatum or physiological saline. The composition is delivered to the ocular surface in an amount and for a time sufficient to alleviate the symptoms of dry eye.

Abstract: This invention relates to a pharmaceutical composition for use in the treatment of pain and inflammation and the treatment of acid indigestion, sour stomach, heartburn and symptoms of upset stomach associated with these conditions in a mammalian organism, said composition comprising:(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen, or a salt thereof, substantially free of (R)-ibuprofen;(ii) an amount effective in the treatment of acid indigestion, sour stomach and/or heartburn of at least one of the antacids; and(iii) optionally, an amount effective in treating excess gas and flatulence of an anti-gas agent.

Abstract: An improved method for the production of synthetic hydrotalcites having high purity (99+%) and small particle size (<2 microns) is disclosed. This method used inexpensive and available reactants and is suitable for commercial scale production. A source of magnesium, such as magnesium hydroxide; a source of aluminum from a mixture of alumina trihydrate and an alkali metal aluminate; and a source of carbonate, such as sodium bicarbonate, are reacted under hydrothermal conditions at a temperature of between 160.degree.-200.degree. C. to produce synthetic hydrotalcite.

Abstract: The present invention relates to a biologically active substance that is stable in the rumen of ruminants and released in the abomasum and its subsequent digestive tract. The biologically active substance has the additional properties of being digested and absorbed with good efficiency.

Abstract: A tableting aid including magnesium carbonate and an oil adsorbed thereon provides useful lubricating and disintegration properties. A free-flowing particulate flavoring additive including magnesium carbonate and a flavor oil adsorbed thereon, is also described.

Abstract: A method utilizing compositions for topical application which are adapted for the prevention and treatment of viral infections such as Herpes, AIDS and other envelope virus infections are disclosed. The compositions of the present invention produce a synergistic anti-viral effect when used in combination. The formulation contains a humectant such as sorbitol, glycerol, or other comparable compound in the range of 20-80% w/v final concentration, which facilitates structural and/or functional three dimensional disruption or disorientation of the viral envelope. The activation of the destruction of the envelope and subsequent death of the envelope virus is then achieved using combination of inorganic monovalent anions, nonionic detergents and anionic detergents. These monovalent anions can include sodium bicarbonate, sodium thiocyanate, sodium fluoride and sodium chloride at about 0.5 to 5% w/v final concentration; nonionic detergents such as Tween 20 at concentrations of about 0.

Abstract: Dialysis solutions for hemodialysis and the like, are prepared by addition of sufficient acid to lower the pH of a sodium carbonate solution to less than 7.6 under conditions which will retain the carbon dioxide generated by such acid addition and mixing the thus produced solution with a solution of the other ions required in such a dialysis solution, again under conditions which will retain the carbon dioxide, to provide a dialysis solution which, under working conditions, will not cause finely divided precipitates of calcium carbonate to form.

Abstract: An aqueous composition for reducing pain at the site of injection of local parenteral anesthetic material, for improving the onset thereof, and for increasing its duration, and a means for preparing and dispensing the same, the composition containing a local parenteral anesthetic which in normal doses gives an acid pH of from about 5 to about 6.9, wherein the anesthetic comprises from about 0.5 to about 2.0% weight of the composition, the composition further containing sufficient NaHCO.sub.3 to maintain the pH thereof between about 7.0 and about 7.6, and further containing from about 0.0004 moles of dissolved CO.sub.2 per ml of composition up to the saturation level of dissolved CO.sub.2 at a CO.sub.2 head pressure of up to about 2.5 atmospheres.

Abstract: A topical medicament comprising a dilute aqueous solution of sodium bicarbonate and a transdermal carrier, preferably containing approximately equal proportions by weight of a 3 percent aqueous solution of sodium bicarbonate, and propylene glycol, the resultant solution comrpising about 1.5 weight percent sodium bicarbonate.

Abstract: A pharmaceutical composition is provided for the protection of the oesogastroduodenal mucous membrane, which composition has an active antacid component comprising sufficient guar gum to provide antacid and buffering effect at a pH of from 0.8 to 3.5, and at least one antacid agent other than guar gum in an amount effective as an antacid.

Abstract: A novel aluminum magnesium hydroxy fatty acid compound is disclosed having a general formula, Al.sub.x Mg.sub.y (OH).sub.3x+2y-z R.sub.z.nH.sub.2 O, wherein R is at least one aliphatic monocarboxylic acid group having the formula RCOO.sup.- and comprising from 12 to 22 carbon atoms, and wherein x=2, 2.ltoreq.y.ltoreq.10, z=2, and n is an integer greater than zero. The compound is prepared by a process including placing water and a salt which is one of an alkali metal salt or an ammonium salt of at least one aliphatic monocarboxylic acid having from 12 to 22 carbon atoms in a reactor fitted with heating and stirring means. The salt is dissolved by intensive stirring and by heating to a temperature ranging from 20.degree. to 90.degree. C. to provide a salt solution. The pH of the salt solution in the reactor is maintained at a pH of at least 8 to provide an alkaline solution.

Abstract: A method of reducing cracking and peeling of human fingernails and toenails and, apparently, of polishing and hardening and toughening them. A finely divided powder comprising substantially pure dolomite is provided. The powder is manually rubbed on the fingernails for periods on a regular schedule. After a short time, fingernails that had previously been subject to chipping and cracking are found to resist chipping and cracking and to appear to have a harder and tougher surface.

Abstract: A process for the preparation of a viscosity-stable antacid composition containing an alginic acid salt comprising reacting an antacid material with said salt at elevated temperatures to form a reaction product and recovering said reaction product in stabilized form.

Abstract: A composite which is obtainable by mixing calcium pantothenate with a per se neutral or basic magnesium or calcium lactate or carbonate in the presence of water and/or a lower alcohol, and drying the resulting mixture, is stable with little decrease of the content of calcium pantothenate during storage.When other drugs, which may cause changes as the result of combination with calcium pantothenate, are combined to produce various preparations, the composite is stable because they are hardly affected by other ingredients and hardly affect other ingredients; for example, in production of tablets, powders, granules, and capsules, complicated processes to separate from other ingredients are not required, and the excessive amount in anticipation of the loss along with time can be reduced markedly.

Abstract: A wet granulate is provided for therapeutically useful substances having a water solubility 10 wt % or less and microcrystalline or microfine cellulose or a mixture of both, where substantial amounts of wet binders are avoided.Tableting mixtures with the new granulate possess a good flow pattern and may be compressed to tablets which show an excellent disintegration behavior.

Abstract: A process for producing a dawsonite with a short-prismatic, isometric crystal habit. The dawsonite can be produced without occupational medicine concerns and can be used as, among other things, a flame-retardant additive in plastics.

Abstract: A method for producing amorphous aluminocarbonate compounds which comprises continuously recirculating a first aqueous solution from a reaction vessel through a recycle system and injecting a gas comprising carbon dioxide into the first solution at a turbulent area located in the recycle system. A second aqueous solution is added to the first solution while the gas injection is continued, and the pH of the resulting mixture is maintained in the approximate range of from 8 to 10. The gas injection is discontinued when the entire amount of the second solution has been added to the first solution, in order to allow further precipitation of the amorphous compound. The method is particularly adapted for producing amorphous sodium aluminocarbonate and sodium magnesium aluminocarbonate.

Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula ##STR1## wherein R.sup.1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylaklyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R.sup.2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R.sup.3 and R.sup.5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R.sup.4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt of magnesium and/or a basic inorganic salt of calcium, is physically stable.

Abstract: Eggshells are utilized after preliminary treatment for medical purposes for treating certain diseases and to compensate for deficiencies of mineral in living tissues, particularly in bone tissues in a form which is acceptable by the body.

Abstract: A mouth cleansing composition for removing dried secretion deposits in and around a user's oral cavity is disclosed. The composition is a mixture of an aqueous salt containing solution, glycerin, hydrogen peroxide, and an acid neutralizing agent.

Abstract: The present invention relates to apparatus, systems and methods for facilitating distribution of bicarbonate concentrate for use in hemodialysis. More particularly, the present invention relates to a centralized bicarbonate concentrate circulatory system for automatically controlled distribution and recirculation of bicarbonate concentrate to service a plurality of remote hemodialysis stations while achieving necessary control of various bicarbonate concentrate characteristics, including concentration, acidity and temperature, as well as the degree of contaminants.

Abstract: Orally ingestible liquid compositions for suspending therein orally administrable pharmaceutically active compositions comprising triglycerides, propylene glycol ester, or monoacetylated glycerides of medium chain length alkanoic acids, polyglycerol esters, and colloidal silicon dioxide.

Abstract: A pelletized feed supplement is supplied which effectively increases productivity of animals fed high acid producing diets. The pelletized feed supplement can also be used to neutralize stomach acid of humans and to maintain a proper electrolyte balance. A method is taught of producing the pelletized feed supplement which results in a buffering agent which is dissolved gradually, and has a high buffering capacity.

Abstract: The invention relates to the production of a new pharmaceutical preparation of high acid-binding capacity, of delayed effect, of increased bioavailability for neutralization of gastric acid and eventually to other pharmaceutical preparations acting in the gastrointestinal tract, first of all of laxative effect by mixing 100 parts by mass of a powdered basic magnesium compound or the powdered mixture of basic magnesium compounds and basic aluminum compounds with 2-2500 parts of a dry or water-swollen organic acid of polymeric character and therapeutically acceptable, e.g. cellulose-glycolic acid, starch-glycolic acid or polymer acrylic and/or methacrylic acid, letting this powdered mixture to stand for 1-24 hours at the temperature of 20.degree.-80.degree. C.

Abstract: An ophthalmic preparation and a method for preparing the ophthalmic preparation is described. The ophthalmic preparation has an enhanced ability to permit essentially normal maintenance of ocular surface mucus-containing goblet cells while present in the eye.

Abstract: Disclosed is a method for producing hydrotalcite in high yield including reacting activated magnesia with an aqueous solution containing aluminate, carbonate, and hydroxyl ions. The method further includes a first step of heating magnesium carbonate or magnesium hydroxide to a temperature between about 500.degree.-900.degree. C. to form activated magnesia or magnesium oxide. The method is suited to producing synthetic hydrotalcite from industrial Bayer liquor.

Abstract: A pharmaceutical composition including magnesium alginate and an antacid material useful in the treatment of reflux esophagitis.

Abstract: A pharmaceutical composition suitable for oral adminstration comprising particulate cimetidine suspended in an aqueous phase containing a buffer which maintains the pH at greater than 7 and a suspending agent.

Abstract: Disclosed is a method for producing hydrotalcite in high yield including reacting activated magnesia with an aqueous solution containing aluminate, carbonate, and hydroxyl ions. The .[.method further includes a first step of.]. .Iadd.activated magnesia is produced by .Iaddend.heating magnesium carbonate or magnesium hydroxide to a temperature between about 500.degree.-900.degree. C. .[.to form activated magnesia or magnesium oxide..]. The method is suited to producing synthetic hydrotalcite from industrial Bayer liquor.

Abstract: A pharmaceutical composition comprises magnesium oxide, hydroxide or a non-toxic salt of magnesium in a slow-release carrier; this material may be combined with or co-prescribed with a diuretic or cardiac glycoside or adrenergic receptor blocking agent or a calcium antagonist for the treatment of hypertension or angina pectoris.